A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients

Completed · Phase 4 · Has a placebo group

Conditions studied: Pruritis

In brief

Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective. Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an important role in the skin and is effective in treatment of certain skin conditions that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients. The objective of the investigators study is to determine the effect of supplementation with oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.

Key facts

Study ID

NCT01114672

Run by

Winthrop University Hospital

People needed

50

Starts

2010-07-01

Expected to finish

2012-02-01

Last updated by the study team

2013-02-21

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hemodialysis treatment for > 3 months
• Subjective complaint of excessive itching

You may not qualify if…

• Age < 18 years
• Failure to provide informed consent
• Intact PTH < 70 pg/ml or > 1,000 pg/ml
• Serum phosphorus > 7.0
• Serum calcium (adjusted for albumin)> 11
• Active malignancy
• Likelihood of imminent renal transplantation
• Current ergocalciferol treatment

Where it is running

• Winthop Univ Hospital Outpatient Dialysis at Bethpage — Bethpage, New York, United States
• Winthrop Univ Hospital Outpatient Dialysis — Mineola, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.